Navigation Links
Sinovac Reports Third Quarter 2008 Unaudited Financial Results
Date:11/18/2008

BEIJING, Nov. 18 /PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA), a leading developer and provider of vaccines in China, today announced the Company's financial results for the three-month and nine-month periods ended September 30, 2008.

    Highlights
    -- Sales year-to-date increased 40% year-over-year to $34.1 million
    -- Operating income year-to-date rose 22.5% year-over-year to $12.4
       million
    -- Net income year-to-date maintained at same level year-over-year at $5.6
       million, inclusive of 25% income tax rate for 2008 versus 15% for 2007
    -- Cash and cash equivalents increased 9% to $20.5 million, compared to
       the second quarter of 2008, due to improved accounts receivable
       collection

Mr. Weidong Yin, Chairman, President and CEO, commented, "Our nine month sales growth was in line with our previously stated objective to increase sales by 35% to 45% over the prior year. As we continue to execute our business plan, management is very confident that the Company is on track to achieve the projected full year sales growth rate for 2008. At the same time, we have increased our investment in research and development in order to focus on long-term growth. The development of a vaccine against human enterovirus 71 (EV 71), which causes hand, foot, and mouth disease, is one of our R&D programs that demonstrate our strategy to develop novel vaccines. We expect this vaccine to become another top-selling flagship product similar to Healive(R), once it is developed and commercialized. Even though we are currently facing challenging financial markets, management continues to prudently execute its long-term growth strategy designed to maximize shareholder value."

Three Months Ended September 30, 2008

For the third quarter 2008, sales were $8.8 million,
'/>"/>

SOURCE Sinovac Biotech Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Sinovac Named to Deloitte Technology Fast 50 China
2. Sinovac to Participate in Two Upcoming Investor Conferences
3. Sinovacs Credit Rating Upgraded to AAZ, Second Highest Rating
4. Sinovac Biotech Holds 2007 Annual General Meeting
5. Sinovac to Present at the 2008 UBS Global Life Sciences Conference
6. Sinovac Initiates Clinical Trials for Inactivated Hepatitis A Vaccine in Ukraine
7. Sinovac Launches Seasonal Influenza Vaccine Anflu(R) for 2008-2009 Flu Season
8. Sinovac Adjourns Annual General Meeting
9. Sinovac to Present at the Susquehanna Financial Groups Second Annual Beijing Management Summit Conference
10. Sinovac Reports Record Second Quarter 2008 Unaudited Financial Results
11. Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... TaiGen Biotechnology Company, Limited ("TaiGen") today announced that they ... Russian pharmaceutical company, to develop and commercialize nemonoxacin (Taigexyn ... , Turkey and other members ... antibiotic for the treatment of bacterial infections including those ...
(Date:1/14/2014)...  3D Communications, a leading provider of strategic communications services to corporations ... in the United States and ... , JD, is returning to the firm,s Washington, D.C. ... after more than two years of service as Associate Commissioner for ...
(Date:1/14/2014)... BETHESDA, Md. , Jan. 14, 2014 ... two institutes from the National Institutes of Health (NIH) ... safer, more effective treatments to patients on a faster ... Advancing Translational Sciences (NCATS) and the National Eye Institute ...
(Date:1/14/2014)... Rockville, MD (PRWEB) January 14, 2014 ... dedicated to developing innovative information technology solutions for ... other health care stakeholders, announced today the signing ... the US Food and Drug Administration (FDA). ...
Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Former FDA Associate Commissioner Returns To 3D Communications 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
... Niceware International , a Milwaukee developer of bar ... seen identification software used to track parts in the ... matter of time before healthcare facilities came calling for ... 2002, has produced NiceLabel software for the automatic identification ...
... since the debut of MedTech Futures and it has been ... share ideas with through this forum. As this column enters ... briefly summarize some of the perspectives over the past year ... - namely personalized medicine. , , Medical technology and pharmaceuticals ...
... the state Division of Enterprise Technology is ... recently released audit of state information technology projects. , ... said he concurs with all the recommendations contained in ... executive-level agencies report by Oct. 1 of this year ...
Cached Biology Technology:Software company enters health space with RFID solutions on hold 2Software company enters health space with RFID solutions on hold 3Personalized medicine and technology convergence 2Personalized medicine and technology convergence 3Personalized medicine and technology convergence 4Personalized medicine and technology convergence 5Personalized medicine and technology convergence 6Personalized medicine and technology convergence 7Personalized medicine and technology convergence 8State technology chief endorses IT audit recommendations 2State technology chief endorses IT audit recommendations 3
(Date:4/23/2014)... 2014) A team of researchers in ... into the brains of nonhuman primates and assessed ... months found that the hNSCs had differentiated into ... tumors. , The study will be published in ... but is currently freely available on-line as an ...
(Date:4/23/2014)... the energy landscape in the U.S., but in ... the energy industry, residents and agricultural interests over ... degraded water quality is a potential risk unless ... in the ACS journal Environmental Science & ... point out that a major criticism of extracting ...
(Date:4/23/2014)... most comprehensive study to date of the family ... more effective vaccine strategies and reveals surprising findings ... results could alter public health strategies to control ... each year. , Genomic analysis of 343 strains ... around the world collected over the last 100 ...
Breaking Biology News(10 mins):Study finds long-term survival of human neural stem cells transplanted into primate brain 2How to avoid water wars between 'fracking' industry and residents 2Impact of whooping cough vaccination revealed 2
... non-human primates, over 100 billion nerve cells build up ... an attempt is made to perform gene therapy for ... specify a responsible neural circuit out of many complicated ... a target gene into this particular circuit selectively. The ...
... has been named founding director of the George Washington ... further strengthen GW,s role as a leader in science ... As director, Dr. Crandall will define the scientific vision ... and implementation of research plans and organizational structures, with ...
... has not changed since the 2010-11 pilot run of the ... University of Arizona-led binational team of researchers. The 15,000-acre ... home to several endangered species and is a major stopover ... It lies within Mexico,s Biosphere Reserve for the Upper Gulf ...
Cached Biology News:Transgenic technique to 'eliminate' a specific neural circuit of the brain in primates 2GW announces creation of Computational Biology Institute to conduct integrated research 2GW announces creation of Computational Biology Institute to conduct integrated research 3GW announces creation of Computational Biology Institute to conduct integrated research 4Cinega de Santa Clara unchanged after pilot run of Yuma Desalting Plant 2Cinega de Santa Clara unchanged after pilot run of Yuma Desalting Plant 3Cinega de Santa Clara unchanged after pilot run of Yuma Desalting Plant 4
Rabbit polyclonal to Glutathione S Transferase alpha ( Abpromise for all tested applications). Antigen: Full length protein: Human Glutathione S Transferase alpha. Entrez GeneID: 2938 Swi...
Anti-Mouse IgM Heavy Chain:FITC, Clone LO-MM-9, Monoclonal Antibody...
Rabbit polyclonal to FOXJ2 ( Abpromise for all tested applications). entrezGeneID: 55810 SwissProtID: Q9P0K8...
Goat polyclonal to HSPC150 ( Abpromise for all tested applications). entrezGeneID: 29089...
Biology Products: